| Aug 15 |
Cocrystal Pharma GAAP EPS of -$0.53 misses by $0.03
|
| Aug 14 |
Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
|
| Jul 19 |
COCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated…
|
| Jul 18 |
Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
|
| Jul 2 |
COCP: CC-42344 Shows In Vitro Activity Against Avian Influenza A (H5N1)…
|
| Jun 20 |
New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows
|
| Jun 7 |
Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?
|
